📷 Image: Wikimedia Commons / Bollywood Hungama
Business
OPPI chief Anil Matai calls for reimbursement schemes and stable policies to boost pharma innovation in India
✍️ The Week
🗓 27 Oct 2026, 05:48 AM
👁 14
OPPI chief Anil Matai said India must introduce clear reimbursement mechanisms and predictable regulatory policies to spur pharmaceutical innovation.
OPPI chief Anil Matai told The Week that the Indian pharmaceutical sector cannot achieve its full innovative potential without a reliable reimbursement framework. He argued that patients and manufacturers alike are held back when new therapies lack clear pathways for cost recovery.
Matai highlighted that many advanced drugs remain inaccessible because insurers and government schemes do not have structured reimbursement mechanisms. He said a transparent system would encourage companies to invest in research and bring breakthrough medicines to market faster.
The industry leader also urged the government to adopt predictable, long‑term policies that mirror successful models in other major markets. Consistent regulatory guidelines, he noted, would reduce uncertainty and attract both domestic and foreign investment in drug development.
If such measures are implemented, Matai believes India could become a hub for affordable, cutting‑edge pharmaceuticals, benefiting patients across the country while strengthening the nation’s economic growth.
Matai highlighted that many advanced drugs remain inaccessible because insurers and government schemes do not have structured reimbursement mechanisms. He said a transparent system would encourage companies to invest in research and bring breakthrough medicines to market faster.
The industry leader also urged the government to adopt predictable, long‑term policies that mirror successful models in other major markets. Consistent regulatory guidelines, he noted, would reduce uncertainty and attract both domestic and foreign investment in drug development.
If such measures are implemented, Matai believes India could become a hub for affordable, cutting‑edge pharmaceuticals, benefiting patients across the country while strengthening the nation’s economic growth.